arrow
T

Tetsuro Shimakami

Kanazawa University
H指数:29
被引数:2,938

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Trends in the Proportion of Hepatitis C Virus Antibody-Positive Patients Who Could be Considered for Direct-Acting Antiviral Therapy Identified Through Preoperative Testing for Ophthalmic Surgery: A Nationwide Multicenter Real-World Cohort Study in Japan

通过眼科手术术前检测识别出的丙型肝炎病毒抗体阳性患者中可考虑直接抗病毒治疗的患者的比例趋势:一项日本全国多中心真实世界队列研究

2026-09-160
OAAI
A decade of clinical course and prognostic determinants in type 1 autoimmune pancreatitis: insights from a 10-year longitudinal multicenter retrospective study

1型自身免疫性胰腺炎10年临床病程及预后决定因素:一项10年纵向多中心回顾性研究的启示

2026-05-250
OAAI
Employment Status of Patients With Liver Disease: A Nationwide Questionnaire Survey in Japan

肝病患者就业状况:一项在日本进行的国家问卷调查

2025-10-040
OAAI
Vascular Endothelial Growth Factor Receptor 2-Targeted Therapy Suppresses the Progression of Alpha-Fetoprotein-Positive Hepatocellular Carcinoma After Combination Therapy With Anti-Programmed Death-Ligand 1 and Anti-Vascular Endothelial Growth Factor-A Antibodies

血管内皮生长因子受体2靶向治疗抑制了联合程序性死亡配体1抗体和血管内皮生长因子A抗体治疗后,甲胎蛋白阳性肝细胞癌的进展。

2025-10-010
OAAI
Transcription factor JUNB is required for transformation of EpCAM-positive hepatocellular carcinoma (HCC) cells into CD90-positive HCC cells in vitro

转录因子JUNB对于在体外将EpCAM阳性的肝细胞癌(HCC)细胞转化为CD90阳性的HCC细胞是必需的。

2025-04-190
OA
The efficacy and safety of adding hepatic arterial infusion chemotherapy using cisplatin to lenvatinib for advanced hepatocellular carcinoma

顺铂加肝动脉灌注化疗联合来伐替尼治疗晚期肝癌的疗效和安全性

2025-04-010
PRE
High-Throughput Screening of Antiviral Compounds Using a Recombinant Hepatitis B Virus and Identification of a Possible Infection Inhibitor, Skimmianine
2024-08-221
OAAI
Functional involvement of endothelial lipase in hepatitis B virus infection
2023-09-016
OAAI